Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool

被引：0
作者：
Y H Chia
M J Ellis
C X Ma
机构：
[1] Washington University,Department of Medicine, Division of Oncology
[2] Siteman Cancer Center,undefined
[3] Washington University,undefined
来源：
British Journal of Cancer | 2010年 / 103卷
关键词：
breast cancer; oestrogen receptor; neoadjuvant endocrine therapy; genomics; relapse risk;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Neoadjuvant endocrine therapy has been increasingly employed in clinical practice to improve surgical options for postmenopausal women with bulky hormone receptor-positive breast cancer. Recent studies indicate that tumour response in this setting may predict long-term outcome of patients on adjuvant endocrine therapy, which argues for its broader application in treating hormone receptor-positive disease. From the research perspective, neoadjuvant endocrine therapy provides a unique opportunity for studies of endocrine responsiveness and the development of novel therapeutic agents.
引用
收藏
页码：759 / 764
页数：5
相关论文
共 517 条
[1]  
Alba E(2010)Chemotherapy (CT) versus hormone therapy (HT) as neoadjuvant treatment in luminal breast cancer: a multicenter, randomized phase II study (GEICAM/2006-03) J Clin Oncol 28 7s-2637
[2]  
Calvo L(2009)Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer J Clin Oncol 27 2630-83
[3]  
Albanell J(1995)Should tamoxifen be a primary treatment choice for elderly breast cancer patients with locoregional disease? Breast Cancer Res Treat 34 77-1667
[4]  
De la Haba J(2006)Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer JAMA 295 1658-420
[5]  
Chacon J(2001)Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy Cancer J 7 413-2103
[6]  
Arcusa Lanza A(2006)Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative ‘Arimidex’ Compared to Tamoxifen (PROACT) trial Cancer 106 2095-3962
[7]  
Sanchez Rovira P(2009)PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer Cancer Res 69 3955-1005
[8]  
Plazaola A(2010)Genome remodelling in a basal-like breast cancer metastasis and xenograft Nature 464 999-2492
[9]  
Lopez Garcia-Asenjo J(2005)Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer – a study from the IMPACT trialists J Clin Oncol 23 2477-170
[10]  
Lluch A(2007)Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer J Natl Cancer Inst 99 167-1717
12345678910